- $488.07m
- $320.48m
- $10.84m
Brief: Glycomimetics Announces Results Of Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics Inc reports results for the quarter ended in December - Earnings Summary
GlycoMimetics Inc expected to post a loss of 15 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Lamb Weston, Dyne Therapeutics
U.S. STOCKS ON THE MOVE-Home Depot, Dollar General, Conagra
GlycoMimetics rises as sickle cell disease therapy shows promise
Brief: GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
Brief: Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Brief: GlycoMimetics Says Entered Into Project Agreement With Patheon Manufacturing Services
GlycoMimetics Inc reports results for the quarter ended in September - Earnings Summary
Brief: GlycoMimetics Q3 basic EPS USD -0.14
GlycoMimetics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: GlycoMimetics Announces First Cohort Dosed In Human Phase 1a Study Of GMI-1687
GlycoMimetics Inc reports results for the quarter ended in June - Earnings Summary
Brief: GlycoMimetics posts Q2 basic EPS USD -0.13
GlycoMimetics Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: GlycoMimetics - US FDA Clears Addition Of Time-Based Final Analysis To Phase 3 Study Of Uproleselan
Brief: Glycomimetics Reports Highlights And Financial Results For First Quarter 2023
GlycoMimetics Inc expected to post a loss of 17 cents a share - Earnings Preview